menu
    • menu
    [{"orgOrder":0,"company":"Aestus Therapeutics","sponsor":"National Institute of Neurological Disorders and Stroke | Symbiance, Inc | Parallax Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fk 614","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Neurology","graph2":"Phase II","graph3":"Aestus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aestus Therapeutics \/ National Institute of Neurological Disorders and Stroke | Symbiance, Inc | Parallax Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Aestus Therapeutics \/ National Institute of Neurological Disorders and Stroke | Symbiance, Inc | Parallax Clinical Research"}]

    Find Clinical Drug Pipeline Developments & Deals for Fk 614

    Menu

    Fk 614

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aestus Therapeutics

                            Country arrow
                            VMX
                            Not Confirmed

                            Aestus Therapeutics

                            Country arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fk 614

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : National Institute of Neurological Disorders and Stroke | Symbiance, Inc | Parallax Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia

                            Details : ATx08-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuralgia, Postherpetic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 18, 2011

                            Lead Product(s) : Fk 614

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : National Institute of Neurological Disorders and Stroke | Symbiance, Inc | Parallax Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.